ClinicalTrials.gg

Program

Lisinopril

Also written as “lisinopril”, “LP-003 Injection” and “LP-005 Injection”.

Its studies are mostly in Hypertension · Chronic Urticaria · Hemoglobinuria, Paroxysmal · Fasting · Rhinitis, Allergic, Seasonal, led by 10 companies.

Furthest: phase 4, since Dec 5, 202538 company-led studies, 11 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Longbio Pharma138 open or runningphase 3since Dec 5, 2025Jun 27, 2023Nov 2026phase 1 · NCT06604949
GlaxoSmithKline60 open or runningphase 3since Apr 13, 2005Apr 13, 2005none ahead
Novartis60 open or runningphase 4since Sep 12, 2005Sep 10, 2005none ahead
IPCA Laboratories40 open or runningphase 1since Nov 5, 2012Nov 5, 2012none ahead
Longbio Pharma (Suzhou)33 open or runningphase 2since Apr 23, 2026Apr 23, 2026Jul 16, 2027phase 2 · NCT07816432
Par Health20 open or runningphase 1since Apr 1, 2008Apr 1, 2008none ahead
Ascension Health10 open or runningphase 4since Jan 2, 2018Jan 2, 2018none ahead
Dexa Medica Group10 open or runningno phasesince Sep 1, 2013Sep 1, 2013none ahead
Intarcia Therapeutics10 open or runningphase 1since Dec 21, 2015Dec 21, 2015none ahead
Pharmtechnology10 open or runningphase 1since Sep 20, 2021Sep 20, 2021none ahead

Also a collaborator on its studies: pharmakinetics-laboratories-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 21 studies since Apr 13, 2005.

  1. Sep 20, 2021Pharmtechnology's first study: phase 1 study in BioequivalenceNew to PharmtechnologyPharmtechnology · NCT05061901 · 38 enrolled · Russian Federation
  2. Jun 27, 2023Longbio Pharma's first study: phase 2 study in Rhinitis, Allergic, SeasonalNew to Longbio PharmaLongbio Pharma · NCT06046391 · 180 enrolled · China
  3. Jan 18, 2024Phase 2 study in Chronic UrticariaLongbio Pharma · NCT06228560 · 202 enrolled · China
  4. Feb 3, 20243 phase 1 studiesLongbio Pharma · NCT06294301, NCT06294288, NCT06294275
  5. Sep 14, 2024Phase 1 study in Chronic UrticariaLongbio Pharma · NCT06604949 · 12 enrolled · China
  6. Aug 15, 2025Phase 2 study in Allergic DiseasesLongbio Pharma · NCT07148557 · 6 enrolled · China
  7. Sep 30, 2025Phase 2 study in Hemoglobinuria, ParoxysmalLongbio Pharma · NCT07212426 · 30 enrolled · China
  8. Nov 24, 2025Phase 2 study in Hemoglobinuria, ParoxysmalLongbio Pharma · NCT07266155 · 30 planned · China
  9. Dec 5, 2025Phase 3 study in Rhinitis, Allergic, SeasonalPhase 3 reachedLongbio Pharma · NCT07291284 · 546 enrolled · China
  10. Dec 11, 20252 phase 2 studiesLongbio Pharma · NCT07342803, NCT07313917
  11. Jan 15, 2026Phase 2 study in Complement-mediated Renal DiseasesLongbio Pharma · NCT07363265 · 46 planned · China
  12. Apr 23, 2026Longbio Pharma (Suzhou)'s first study: phase 2 study in PeriodontitisNew to Longbio Pharma (Suzhou)Longbio Pharma (Suzhou) · NCT07603713 · 100 planned · China
  13. Aug 14, 2026Phase 2 study in Peanut HypersensitivityLongbio Pharma (Suzhou) · NCT07785063 · 80 planned · United States, Australia, Canada and more
  14. Sep 7, 2026Phase 2 study in Food HypersensitivityLongbio Pharma (Suzhou) · NCT07816432 · 12 planned · China

Ahead

  1. Nov 2026Primary completion: phase 1 study in Chronic UrticariaLongbio Pharma · NCT06604949
  2. Nov 12, 2026Primary completion: phase 2 study in PeriodontitisLongbio Pharma (Suzhou) · NCT07603713
  3. Feb 28, 2027Primary completion: phase 2 study in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Longbio Pharma · NCT07313917
  4. Jul 16, 2027Primary completion: phase 2 study in Food HypersensitivityLongbio Pharma (Suzhou) · NCT07816432

TargetBeta

ACE →read by rule
“An orally bioavailable, long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity”NCIt, by rule
“Angiotensin-converting enzyme inhibitor”ChEMBL 37, by rule

Studies

All 38 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07816432Food Hypersensitivity · China2Not yet recruitingLongbio Pharma (Suzhou)Jul 16, 202712
NCT07785063Peanut Hypersensitivity · United States, Australia, Canada and more2Not yet recruitingLongbio Pharma (Suzhou)May 202980
NCT07603713Periodontitis · China2Not yet recruitingLongbio Pharma (Suzhou)Nov 12, 2026100
NCT07363265Complement-mediated Renal Diseases · China2Not yet recruitingLongbio PharmaAug 2, 202846
NCT07313917Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) · China2Not yet recruitingLongbio PharmaFeb 28, 2027150
NCT07342803Allergic Asthma · China2RecruitingLongbio PharmaDec 28, 2027200
NCT07291284Rhinitis, Allergic, Seasonal · China3Active, not recruitingLongbio PharmaMar 31, 2026546
NCT07266155Hemoglobinuria, Paroxysmal · China2Not yet recruitingLongbio PharmaDec 30, 202730
NCT07212426Hemoglobinuria, Paroxysmal · China2Active, not recruitingLongbio PharmaMay 6, 202630
NCT07148557Allergic Diseases · China2Active, not recruitingLongbio PharmaMay 31, 20266
NCT06604949Chronic Urticaria · China1Active, not recruitingLongbio PharmaNov 202612
NCT06294288Chronic Urticaria · China1CompletedLongbio PharmaMar 4, 202460
NCT06294275Myelodysplastic Syndromes · China1CompletedLongbio PharmaAug 16, 202368
NCT06294301Hemoglobinuria, Paroxysmal · China1CompletedLongbio PharmaAug 31, 202468
NCT06228560Chronic Urticaria · China2CompletedLongbio PharmaApr 17, 2025202
NCT06046391Rhinitis, Allergic, Seasonal · China2CompletedLongbio PharmaOct 19, 2023180
NCT05061901Bioequivalence · Russian Federation1CompletedPharmtechnologyNov 6, 202138
NCT03392740Heart Failure, Systolic · United States4WithdrawnAscension HealthDec 15, 20180
NCT02641899Healthy · United States1CompletedIntarcia TherapeuticsMar 201633
NCT01936012Healthy · Indonesia–CompletedDexa Medica GroupFeb 201334
NCT01831700Fasting · India1CompletedIPCA LaboratoriesOct 201248
NCT01827878Lecithin Cholesterol Acyltransferase Deficiency · India1CompletedIPCA LaboratoriesOct 201248
NCT01735344Lecithin Cholesterol Acyltransferase Deficiency · India1CompletedIPCA LaboratoriesAug 201240
NCT01735318Fasting · India1CompletedIPCA LaboratoriesAug 201240
NCT00883506Hypertension1CompletedNovartisJun 200024
NCT00883064Hypertension1CompletedNovartisApr 200032
NCT01380431Lecithin Cholesterol Acyltransferase Deficiency · United States1CompletedPar HealthOct 199918
NCT01375244Fasting · United States1CompletedPar HealthOct 199936
NCT00552708Hypertension · United States1CompletedGlaxoSmithKlineDec 200755
NCT00557128Hypertension · United States1CompletedGlaxoSmithKlineDec 200724
NCT00549510Hypertension · United States1CompletedGlaxoSmithKlineDec 200729
NCT00508365Hypertension · United States1CompletedGlaxoSmithKlineJun 3, 200862
NCT00347360Hypertension · United States3CompletedGlaxoSmithKlineApr 2008654
NCT00241124Hypertension · Germany4CompletedNovartisJun 20051,099
NCT00171600Hypertension · Switzerland4TerminatedNovartisJan 200754
NCT00171574Hypertension · Switzerland4CompletedNovartisJul 2006124
NCT00171067Hypertension · Germany, Switzerland3CompletedNovartisMay 2007134
NCT00108082Hypertrophy, Left Ventricular · United States3CompletedGlaxoSmithKlineAug 2008287

How it is read

Names in the registry

  • “Lisinopril”, 10 entries
  • “lisinopril”, 5 entries
  • “LP-003 Injection”, 4 entries
  • “LP-005 Injection”, 4 entries
  • “LP-003”, 2 entries

Codes read as this program: LP003, LP005, LP001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.